High density of peritumoral lymphatic vessels is a potential prognostic marker of endometrial carcinoma: A clinical immunohistochemical method study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Gao, Ying ^a   Liu, Zi ^a   Gao, Fei ^a   Meng, Xiao yu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEIN LYVE 1; TUMOR PROTEIN; UNCLASSIFIED DRUG; LYMPHATIC VESSEL ENDOTHELIAL HA RECEPTOR 1 PROTEIN, HUMAN; LYMPHATIC VESSEL ENDOTHELIAL HA RECEPTOR-1 PROTEIN, HUMAN; VESICULAR TRANSPORT PROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DENSITY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STAINING; SURVIVAL RATE; BIOSYNTHESIS; ENDOMETRIUM TUMOR; LYMPHANGIOGENESIS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; SURVIVAL RATE; VESICULAR TRANSPORT PROTEINS;

EID: 77950672920     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-131     Document Type: Article

References (33)

1. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000, 13:295-308. 10.1038/modpathol.3880051, 10757340.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005, 366:491-505. 10.1016/S0140-6736(05)67063-8, 16084259.
3. Kyo S, Hashimoto M, Maida Y, Mizumoto Y, Nakamura M, Takakura M, Inoue M. Analysis of outcome of Stage I-III endometrial cancer treated with systematic operation omitting paraaortic lymphadenectomy. Eur J Gynaecol Oncol 2007, 28:170-173.
4. Kato T, Prevo R, Steers G, Roberts H, Leek RD, Kimura T, Kameoka S, Nishikawa T, Kobayashi M, Jackson DG, Harris AL, Gatter KC, et al. A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer 2005, 93:1168-1174. 10.1038/sj.bjc.6602844, 2361506, 16251871.
5. Gao P, Zhou GY, Zhang QH, Xiang L, Zhang S, Li C, Sun YL. Clinicopathological significance of peritumoral lymphatic vessel density in gastric carcinoma. Cancer Lett 2008, 263:223-230. 10.1016/j.canlet.2008.01.017, 18289774.
6. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001, 276:19420-19430. 10.1074/jbc.M011004200, 11278811.
7. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999, 144:789-801. 10.1083/jcb.144.4.789, 2132933, 10037799.
8. Afifty AM, Craiq S, Paulino AF, Stern R. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol 2005, 9:312-318. 10.1016/j.anndiagpath.2005.07.004, 16308159.
9. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001, 6:317-321.
10. Saddik M, Lai R. CD44s a surrogate marker for distinguishing intraductal papilloma from papillary carcinoma of the breast. J Clin Pathol 1999, 52:862-864. 10.1136/jcp.52.11.862, 501606, 10690183.
11. Ohno M, Nakamura T, Kunimoto Y, Nishimura K, Chung-Kang C, Kuroda Y. Lymphagenesis correlates with expression of vascular endothelial growth factor Cincolorectal cancer. Oncol Rep 2003, 10:939-943.
12. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993, 10:302-313.
13. Witte MH, Jones K, Wilting J, Dictor M, Selq M, Mchale N, Gershenwald JE, Jackson DG. Structure function relationships in the lymphatic system and implications for cancer biology. Cancer Metastasis Rev 2006, 25:159-184. 10.1007/s10555-006-8496-2, 16770531.
14. Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, Poll-Franse LV. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett 2007, 254:128-136. 10.1016/j.canlet.2007.03.001, 17442484.
15. Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, Levick JR, Orlando A, Bates DO. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004, 90:693-700. 10.1038/sj.bjc.6601571, 2409610, 14760386.
16. Gao F, Lu YM, Cao ML, Liu YW, He YQ, Wang Y. Expression and quantification of LYVE-1 in human colorectal cancer. Clin Exp Med 2006, 6:65-71. 10.1007/s10238-006-0097-4, 16820993.
17. Omachi T, Kawai Y, Mizuno R, Nomiyama T, Miyaqawa S, Ohhashi T, Nakayama J. Immunohistochemical demonstration of proliferating lymphatic vessels in colorectal carcinoma and its clinicopathological significance. Cancer Lett 2007, 246:167-172. 10.1016/j.canlet.2006.02.013, 16574316.
18. Donoghue JF, Lederman FL, Susil BJ, Rogers PA. Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma. Hum Reprod 2007, 22:1705-1713. 10.1093/humrep/dem037, 17347164.
19. Red-Horse K, Rivera J, Schanz A, Zhou Y, Winn V, Kapidzic M, Maltepe E, Okazaki K, Kochman R, Vo KC, Giudice L, Erlebacher A, et al. Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation. J Clin Invest 2006, 116:2643-2652. 1570373, 16998586.
20. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Gatter KC, Harris AL, Jackson DG. LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol 2005, 58:202-206. 10.1136/jcp.2004.019174, 1770560, 15677543.
21. Tripp CH, Haid B, Flacher V, Sixt M, Peter H, Farkas J, Gschwentner R, Sorokin L, Romani N, Stoitzner P. The lymph vessel network in mouse skin visualised with antibodies against the hyaluronan receptor LYVE1. Immunobiology 2008, 213:715-728. 10.1016/j.imbio.2008.07.025, 18926287.
22. Carr I, Orr FW. Invasion and metastasis. Can Med Assoc J 1983, 128(10):1164-1167. 1875302, 6340812.
23. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003, 162:1951-1960. 1868148, 12759251.
24. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003, 9:250-256.
25. Audet N, Bersley NJ, Mac Milllan C, Jackson DG, Gullane P, Kamel-Reid S. Lymphatic Vessel Density, Nodal Metastases, and Prognosis in Patients With Head and Neck Cancer. Arch Otolaryngol Head Neck Surg 2005, 131:1065-1070. 10.1001/archotol.131.12.1065, 16365219.
26. Achen MG, Stacker SA. Molecular Control of Lymphatic Metastasis. Ann N Y Acad Sci 2008, 1131:225-34. 10.1196/annals.1413.020, 18519975.
27. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886. 10.1126/science.1071420, 11976409.
28. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004, 64:5702-5711. 10.1158/0008-5472.CAN-04-0389, 15313910.
29. Paltian V, Alldinger S, Baumgärtner W, Wohlsein P. Expression of CD44 in Canine Mammary Tumours. J Comp Path 2009, 1-11.
30. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 2004, 53:567-579. 10.1007/s00262-003-0494-4, 14762695.
31. Gargett CE, Schwab KE, Zillwood RM, Nguyen HP, Wu D. Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod 2009, 80:1136-1145. 10.1095/biolreprod.108.075226, 19228591.
32. Goodison S, Tarin D. Clinical implications of anomalous CD44 gene expression in neoplasia, Front. Biosci 1998, 3:e89-e109.
33. Miyake H, Eto H, Arakawa S, Kamidono S, Hara I. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 2002, 167:1282-1287. 10.1016/S0022-5347(05)65282-2, 11832714.